Alert
This site has not been optimised for Internet Explorer due to Microsoft no longer providing support for the browser. Please view this site using another browser such as Google Chrome or Microsoft Edge.
Lung cancer single map Consumer summary document

 

The lung cancer domain of the Atlas of Healthcare Variation gives clinicians, patients and providers an overview of the diagnosis and treatment of lung cancer in New Zealand, by district health board (DHB) and regional cancer network (RCN).

Lung cancer, as a high volume cancer with large inequities and a relatively poor survival rate, continues to have the greatest impact on overall cancer morbidity and mortality in New Zealand. Two reports recently published by the Ministry of Health show[1, 2]:

  • lung cancer accounted for the most cancer-related deaths
  • lung cancer accounts for nearly a third of all Māori cancer deaths
  • one- and five-year survival rates remain poorer for Māori than non-Māori
  • people who live in areas of high deprivation are also disproportionately affected by lung cancer, with men 3.2 times more likely to be diagnosed with lung cancer than men living in the least deprived areas. 

International cancer data from GLOBOCAN shows New Zealand male age-standardised rates (ASRs) were lower than both the United Kingdom and Australia[3]. In contrast, female ASRs were higher than Australia but lower than the United Kingdom.

The cancer pathway, from presentation of the patient at a health care service to diagnosis, treatment (surgery, chemotherapy, radiotherapy or palliative care) and end-of-life care, was used as a framework for considering potential lung cancer indicators.

Lung cancer

Last updated: 3rd December, 2021